New Patent will be awarded to Triton Thalassic Technologies Incorporated

Ridgefield, CT. ------ May 05, 2006

Press Release - Ridgefield, CT. – June 5, 2006

Mr. Barry Ressler, Chairman and Chief Executive Officer of Triton Thalassic Technologies, Inc. (T3I), announced today that the United States Patent Office has issued notification that a New Patent will be awarded to Triton Thalassic Technologies Incorporated on June 6, 2006 entitled "Monochromatic Fluid Treatment Systems (Non-Laser Light Source," The patent addresses methods, systems and apparatus for photo processing of fluids, particularly complex fluids, such as blood products, pharmaceuticals, injectables and vaccines. The patent further covers disclosed methods and systems that employ Triton's non-laser light source(s) to generate monochromatic light energy, preferably in the range of 260 nm to 310 nm, for fluid treatment. Advantageous processing regimens and/or adjunct additives and/or agents may also be used to achieve desired and/or enhanced results, e.g., inactivation of pathogens, bacteria and/or viruses, modulation of immune response, and/or leukoreduction. Of particularly importance is that the patent includes specific wavelengths, novel temperature control systems and geometric/structural arrangements that provide enhanced processing results and/or efficiencies. The methods, systems and apparatus achieve desirable results in a broad range of diagnostic, therapeutic and treatment applications, and generally provide enhanced operating efficiencies and/or processing results in application modalities that employ a broad range of photo-activated and/or photo-responsive materials and/or compounds. Further to this addition to Triton's patent portfolio, 4 pending patents are anticipated for pharmaceutical process, ophthalmic product sterilization, sterile food packaging and a novel sterilization delivery system.

Triton Thalassic Technologies, Inc. (T3I) has developed, patented and manufactures treatment systems that control and minimize bacterial and viral contamination in a variety of applications using only ultraviolet (UV) light energy. This proprietary technology is being applied to a variety of fluids (industrial fluids, process water, beverages, and biologics) and other products in the pharmaceutical, healthcare, food, nutritionals and specialty packaging markets. T3I’s patented process uses the world’s highest powered excimer light source as the sole means for effective pathogen inactivation without the need for chemical or thermal treatment. As a result, the Triton regimen preserves the structure and performance characteristics or value of the product being treated compared with other more destructive (chemical and thermal) decontamination or disinfection technologies. The Triton light source does not incorporate mercury gases and is therefore a more environment-friendly technology compared with conventional mercury UV light sources.

The company welcomes prospective customers with fluid contamination questions and challenges to use our convenient inquiry response form.